Home » Peregrine Submits Tarvacin Antiviral Investigational New Drug Application
Peregrine Submits Tarvacin Antiviral Investigational New Drug Application
May 6, 2005
Peregrine Pharmaceuticals has submitted an investigational new drug application (IND) to the FDA to initiate a Phase I clinical trial using Tarvacin to treat patients with chronic hepatitis C virus infection.
The objectives of the Phase I clinical protocol submitted in the IND are to evaluate safety, pharmacokinetics and viral load in patients chronically infected with hepatitis C virus who have failed standard treatment. There are estimated to be 2.7 million people in the U.S. and 170 million people worldwide with chronic hepatitis C infection.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct